Fourth, although the use of antihypertensive drugs, oral hypoglycaemic drugs and insulin was taken into account in the regression analysis, we were not able to determine whether there were changes either in diabetes medication (e.g., initiation of SGLT2i or GLP-1 receptor agonists) or in concomitant medications that might have affected weight or CV risk factors (e.g., initiation of or change in the dose of statin) during the course of this study. Here, GLP1R is linked to diabetes mellitus.